By alleviating negative regulation of T-cell activation, antibodies targeting inhibitory immune checkpoint proteins, including programmed death 1 (PD-1), its ligand PD-L1, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have produced durable clinical responses in a subset of cancer patients (8–10). This evidence concerns the gene CTLA4 and cancer.